Sabine Wittemer‐Rump

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

Henryk Barthel, Hermann‐Josef Gertz, S. Dresel et al. · The Lancet Neurology · 2011 · 574 citations

Neurodegenerative Diseases, Diagnostic Study, Alzheimer's Disease +7

Pasotuxizumab, a Bite ^® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Immunotherapy · 2020 · 132 citations · Full text

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Sung‐Bae Kim, Funda Meric‐Bernstam, Aparna Kalyan et al. · Targeted Oncology · 2019 · 74 citations · Full text

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz et al. · Cancer Research · 2016 · 73 citations

Pathology, Tumor Biology, Preclinical Efficacy +16

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Journal of Clinical Oncology · 2019 · 56 citations

Mcrpc Pts, Genitourinary Cancer, Medicine +15